Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.635
-0.015 (-2.25%)
Dec 20, 2024, 4:00 PM EST - Market closed
Karyopharm Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 72.83 | 52.23 | 135.19 | 190.46 | 85.92 | 128.86 | Upgrade
|
Short-Term Investments | 60.7 | 139.21 | 142.78 | 38.16 | 163.32 | 133.1 | Upgrade
|
Cash & Short-Term Investments | 133.53 | 191.44 | 277.97 | 228.62 | 249.24 | 261.96 | Upgrade
|
Cash Growth | -35.90% | -31.13% | 21.59% | -8.28% | -4.85% | -20.18% | Upgrade
|
Receivables | 31.78 | 27.96 | 54.89 | 23.9 | 12.88 | 7.86 | Upgrade
|
Inventory | 4.67 | 3.04 | 4.22 | 4.11 | 2.64 | 0.35 | Upgrade
|
Prepaid Expenses | 14.75 | 10.81 | 12.02 | 12.64 | 9.29 | 7.29 | Upgrade
|
Restricted Cash | 0.03 | 0.66 | 1.06 | 6.35 | 2.48 | 1.12 | Upgrade
|
Total Current Assets | 184.76 | 233.92 | 350.16 | 275.61 | 276.53 | 278.57 | Upgrade
|
Property, Plant & Equipment | 3.08 | 4.88 | 7.38 | 9.56 | 11.58 | 13.66 | Upgrade
|
Long-Term Investments | - | - | - | - | 24.22 | 2.02 | Upgrade
|
Long-Term Accounts Receivable | - | - | - | 19.51 | - | - | Upgrade
|
Other Long-Term Assets | 1.64 | 1.64 | 0.63 | 0.64 | 0.72 | 0.71 | Upgrade
|
Total Assets | 189.48 | 240.44 | 358.17 | 305.31 | 313.05 | 294.96 | Upgrade
|
Accounts Payable | 5.78 | 3.12 | 2.77 | 1.6 | 4.45 | 0.99 | Upgrade
|
Accrued Expenses | 50.11 | 61.39 | 58.42 | 69.12 | 52.93 | 40.88 | Upgrade
|
Current Portion of Leases | 3.67 | 3.31 | 2.87 | 2.32 | 1.92 | 1.65 | Upgrade
|
Current Unearned Revenue | - | - | - | - | 0.3 | 2.34 | Upgrade
|
Other Current Liabilities | 1.94 | 1.65 | 1.85 | 0.68 | 0.61 | 0.5 | Upgrade
|
Total Current Liabilities | 61.49 | 69.48 | 65.91 | 73.72 | 60.2 | 46.35 | Upgrade
|
Long-Term Debt | 264.09 | 303.4 | 302.82 | 302.29 | 191.02 | 183.45 | Upgrade
|
Long-Term Leases | - | 2.79 | 6.1 | 8.97 | 11.29 | 13.2 | Upgrade
|
Long-Term Unearned Revenue | - | - | - | - | - | 2.19 | Upgrade
|
Other Long-Term Liabilities | 23.54 | 0.98 | - | - | - | - | Upgrade
|
Total Liabilities | 349.12 | 376.64 | 374.83 | 384.98 | 262.5 | 245.19 | Upgrade
|
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Additional Paid-In Capital | 1,373 | 1,351 | 1,328 | 1,099 | 1,120 | 923.14 | Upgrade
|
Retained Earnings | -1,533 | -1,487 | -1,344 | -1,179 | -1,070 | -873.34 | Upgrade
|
Comprehensive Income & Other | -0.22 | -0.16 | -0.64 | 0.19 | 0.52 | -0.04 | Upgrade
|
Shareholders' Equity | -159.65 | -136.21 | -16.66 | -79.67 | 50.55 | 49.77 | Upgrade
|
Total Liabilities & Equity | 189.48 | 240.44 | 358.17 | 305.31 | 313.05 | 294.96 | Upgrade
|
Total Debt | 267.76 | 309.5 | 311.79 | 313.58 | 204.22 | 198.29 | Upgrade
|
Net Cash (Debt) | -134.23 | -118.05 | -33.83 | -84.96 | 45.02 | 63.66 | Upgrade
|
Net Cash Growth | - | - | - | - | -29.28% | -71.77% | Upgrade
|
Net Cash Per Share | -1.13 | -1.03 | -0.41 | -1.13 | 0.62 | 1.03 | Upgrade
|
Filing Date Shares Outstanding | 125.31 | 115.07 | 113.34 | 79.16 | 74.63 | 65.55 | Upgrade
|
Total Common Shares Outstanding | 125.3 | 114.92 | 113.21 | 75.75 | 73.92 | 65.37 | Upgrade
|
Working Capital | 123.26 | 164.44 | 284.25 | 201.89 | 216.33 | 232.22 | Upgrade
|
Book Value Per Share | -1.27 | -1.19 | -0.15 | -1.05 | 0.68 | 0.76 | Upgrade
|
Tangible Book Value | -159.65 | -136.21 | -16.66 | -79.67 | 50.55 | 49.77 | Upgrade
|
Tangible Book Value Per Share | -1.27 | -1.19 | -0.15 | -1.05 | 0.68 | 0.76 | Upgrade
|
Machinery | - | 2.29 | 2.33 | 2.25 | 1.97 | 1.85 | Upgrade
|
Leasehold Improvements | - | 4.88 | 5.45 | 5.45 | 5.44 | 5.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.